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Mutation profiling of cancer drivers 
in Brazilian colorectal cancer
Wellington dos Santos1, Thais Sobanski1, Ana Carolina de carvalho1,  
Adriane Feijó evangelista  1, Marcus Matsushita2, Gustavo Nóriz Berardinelli1, 
Marco Antonio de oliveira1, Rui Manuel Reis  1,3,4 & Denise Peixoto Guimarães1,5
The molecular basis of colorectal cancer (CRC) can guide patient prognosis and therapy. In Brazil, 
knowledge on the CRC mutation landscape is limited. Here, we investigated the mutation profile of 
150 cancer-related genes by next-generation sequencing and associated with microsatellite instability 
(MSI) and genetic ancestry in a series of 91 Brazilian CRC patients. Driver mutations were found in the 
APC (71.4%), TP53 (56.0%), KRAS (52.7%), PIK3CA (15.4%) and FBXW7 (10.9%) genes. Overall, genes 
in the MAPK/ERK, PIK3/AKT, NOTCH and receptor tyrosine kinase signaling pathways were mutated 
in 68.0%, 23.1%, 16.5%, and 15.3% of patients, respectively. MSI was found in 13.3% of tumors, 
most of which were proximal (52.4%, P< 0.001) and had a high mutation burden. European genetic 
ancestry was predominant (median of 83.1%), followed by Native American (4.1%), Asian (3.4%) and 
African (3.2%). NF1 and BRAF mutations were associated with African ancestry, while TP53 and PIK3CA 
mutations were inversely correlated with Native American ancestry. Our study suggests that Brazilian 
CRC patients exhibit a mutation profile similar to other populations and identify the most frequently 
mutated genes, which could be useful in future target therapies and molecular cancer screening 
strategies.
Colorectal cancer (CRC) is the third most common type of cancer worldwide1,2. According to GLOBOCAN, over 
1.8 million new colorectal cancer cases occurred in 2018. Moreover, the disease is the second cause of death by 
cancer worldwide2. Increases in both incidence and mortality have been observed over the last 10 years in several 
Europe, Latin America, and Asia countries1. The most significant increases in incidence were observed in Brazil, 
Costa Rica and Bulgaria1. In Brazil, the Brazilian National Cancer Institute (INCA) estimated that over 36,000 
new cases were expected for 2018, ranking CRC as the third most frequent cancer among men and as the second 
most frequent cancer among women3.
CRC is more frequently observed in the distal colon (left colon, from splenic flexure to rectum) than in the 
proximal side (right colon, from the cecum to transverse colon)4. In addition to incidence differences, the tumors 
arising from the left and right colon are distinct in their epidemiology, biology, histology and microbial diver-
sity4–7. Consequently, it also influences patients’ prognosis4,8.
Several lifestyles are risk factors associated with CRC, such as red and processed meat consumption, alcohol 
intake, smoking and body weight9. Moreover, the cumulative acquisition of genetic alterations leads to a progres-
sive tumorigenesis process from normal to precursor lesion, culminating in a malignant tumor10. The majority 
(80–85%) of CRC cases are sporadic and emerge from somatic alterations in driver genes10. These alterations are 
linked to three main molecular groups: chromosomal instability, mismatch repair defect and methylator pheno-
type7,10. In addition to these classic features, the CRC Subtyping Consortium classified four consensus molecular 
subtypes (CMS) of CRC: CMS1, which are enriched for tumors with MSI, overexpression of DNA damage repair 
proteins, high immune activation and widespread hypermethylation; CMS2, which have tumors with chromo-
somal instability and activation of the WNT and MYC signaling pathways; CMS3, with tumors with epithelial and 
metabolic dysregulation; and CMS4, which have tumors with transforming growth factor-β activation, stromal 
infiltration and angiogenesis6. The molecular profile of CRCs is distinct between proximal and distal tumors. 
Proximal CRCs are associated with microsatellite instability (MSI) and activating mutations on the BRAF gene, 
frequently harboring a high mutation burden, whereas distal CRCs are associated with chromosomal instability 
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and are more frequently non-hypermutated and have less frequently the MSI phenotype6,7. In line with this, prox-
imal CRCs are enriched for CMS1 tumors and, inversely, distal CRC are enriched for CMS2 tumors6.
Molecular characterization is crucial for CRC patient care and prognostic and therapeutic assessment11–13. 
Knowledge of the mutation profile of Brazilian CRC patients is limited. Therefore, the present study aimed to 
interrogate the mutational profile of CRCs by next-generation sequencing mutation analysis of a large panel of 
150 cancer-related genes and to identify significant cancer drivers. Moreover, the molecular profile was associated 
with clinicopathological features and genetic ancestry markers of CRC patients.
Results
Description of the mutation profile. We sequenced 150 cancer-related genes in 91 colorectal tumors. 
The mean read depth of sequencing was 625.7x per gene and 60.7x per variant. Overall, after filtering out non-
driver variants (see Material and Methods), we identified at least one somatic variant for each tumor sample with 
a mean of 3.6 mutations per patient (range 1–20). Thirteen tumors (14.3%) harbored mutations in single genes, 
26 tumors (28.6%) in two genes, 24 tumors (26.4%) in three genes, and 28 tumors (30.8%) harbored alterations in 
four or more genes. Among the 150 genes sequenced, 46 showed at least one driver somatic mutation, including 
missense, frameshift, nonsense, in-frame, and splice mutations (54.9%, 22.6%, 21.3%, 0.9%, 0.3%, respectively). 
The most recurrently altered genes in our study population are shown in Fig. 1 (for a complete list of variants 
identified, see Supplementary Table S1). APC was the most affected gene, altered in 65 tumor samples (71.4%), 
followed by TP53 (51 cases, 56.0%), KRAS (48 cases, 52.7%), PIK3CA (14 cases, 15.4%) and FBXW7 (10 cases, 
10.9%, Fig. 1). Below, we further describe the most affected genes and pathways.
APC gene. A total of 86 somatic mutations in APC were found in 65 tumors (71.4%), among which 44 har-
bored a single mutation, and 21 tumors harbored two mutations in the gene. The majority of the mutations were 
protein truncating: 52 nonsense (60.5%), 30 frameshift (34.8%), and 4 missense (4.7%) (Supplementary Fig. S1 
and Supplementary Table S1). Among the mutations found, 68 were previously reported as somatic mutations 
in CRC (50 nonsense and 14 frameshift), and 22 were new mutations (16 frameshift, 4 missense and 2 nonsense 
mutations). The mutations found are spread widely throughout the coding region of the APC gene, and the most 
affected site was the protein position 1556, which showed frameshift mutations in 6 tumors (Supplementary 
Fig. S1). In addition, nine APC mutated cases were selected and PCR-followed by direct Sanger sequencing was 
performed, validating all mutations (Supplementary Fig. S2).
TP53 gene. Fifty-six mutations on TP53 were found affecting 51 tumors (56.0% of the tumors, Fig. 1 and 
Supplementary Fig. S1), among which 46 harbored a single mutation on the gene and 5 harbored two muta-
tions. The majority of alterations in TP53 were missense mutations (40, 71.4%), followed by nonsense (7 muta-
tions, 12.5%), frameshift (5 mutations, 8.9%), in-frame (3 mutations, 5.4%) and splice region (1 mutation, 1.8%) 
(Supplementary Fig. S1 and Supplementary Table S1). Among the mutations found, 53 were previously reported 
as somatic mutations in CRC (40 missense, 7 nonsense, 3 frameshift, 2 in-frame, and 1 splice region mutations), 
Figure 1. Waterfall plot (oncoplot) of the distribution of mutations found in our tumor samples. The upper 
plot shows the frequency of mutation for each tumor sample. Left and right plots show the frequency of samples 
mutated for proximal colon (left) and distal colon (right). The central plot shows the types of mutations in each 
tumor sample (when the sample showed more than one mutation in the same gene, only the most deleterious 
type is shown). The lower part of the figure shows the tumor stage at diagnosis and microsatellite instability 
status (MSI) of each sample. Tumor stage: stage of the disease at the diagnosis.
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and 3 were new mutations, including 2 frameshift and 1 in-frame mutation. Most mutations were localized on the 
DNA-binding domain (only one mutation was found outside this domain), and the most frequently altered site 
was protein position 273, with 6 missense mutations (Supplementary Fig. S1). In addition, nine TP53 mutated 
cases were selected and PCR-followed by direct Sanger sequencing was performed, validating all mutations 
(Supplementary Fig S2).
MAPK-ERK signaling pathway alterations. The MAPK-ERK signaling pathway had at least one 
mutated gene in 62 tumors (68%). The most frequently altered gene in the MAPK/ERK pathway was KRAS, 
which showed 48 missense mutations, affecting 52.7% of the tumors. All KRAS mutations affected hotspots of the 
gene at protein sites 12 (33 mutations, 68.7% of the KRAS mutations), 13 (8 mutations, 16.7%), 146 (4 mutations, 
8.3%), 61 (2 mutation, 4.2%), and 117 (1 mutation, 2.1%) (Fig. 2, and Supplementary Table S1). All mutations 
on codons 12/13 and codon 61 of the KRAS gene were confirmed by the cobas® KRAS mutation test. The NF1 
gene showed 10 somatic mutations in 8 tumor samples (8.8%), three of which were already known mutations 
(2 missense and 1 nonsense mutations), four were novel missense mutations, and three were novel frameshift 
mutations. The mutations were spread throughout the coding region of the gene. All truncating protein muta-
tions in NF1 were mutually exclusive with KRAS, and four tumors had missense mutations on both KRAS and 
NF1 (Fig. 2a). The BRAF gene was mutated in 8 tumor samples (8.8%), showing 8 missense somatic mutations 
mutually exclusive with KRAS, all previously reported as somatic mutations in CRC. The p.Val600Glu mutation 
Figure 2. Waterfall (oncoplot) plot (a) and mutations mapper (b) of MAPK-ERK signaling pathway genes. 
Tumor stage: stage of the disease at diagnosis. MSI: microsatellite instability.
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(p.V600E) was the most prevalent mutation, occurring in 6 tumors (75% of all mutations on the BRAF gene). The 
two variants, different from V600E mutations, also affected the kinase domain of the BRAF protein (p.Asp594Glu 
and p.Gly469Val). Mutations in the NRAS gene were found in 4 tumor samples (4.4%), 3 at codon 12 (75%) and 
one at codon 61. NRAS mutations were mutually exclusive with KRAS, NF1 and BRAF mutations. Finally, the 
ARAF gene had one previously known missense mutation that was located outside of the main domains of the 
protein (Fig. 2 and Supplementary Table S1).
PI3K-AKT signaling pathway alterations. Genes in the PI3K-AKT signaling pathway were altered in 
21 tumors (23.1%). The most frequently altered gene in the PI3K-AKT signaling pathway was PIK3CA, with 
alterations in 14 tumors (15.4%, Fig. 3a), all harboring already known somatic mutations. The PIK domain of the 
protein harbored most of the mutations found in PIK3CA, 6 mutations at codon 545 (42.9% of all PIK3CA muta-
tions), 2 mutations at codon 542 (14.3%), and 1 mutation at codon 546 (7.1%). The p85-binding domain of the 
protein harbored 1 mutation (7.1%), and the other 4 (28.6%) mutations affected sites outside the main domains of 
the protein (Fig. 3a). The PTEN gene was mutated in 4.4% of the tumors (Fig. 3), showing one previously reported 
missense mutation and one frameshift mutation, along with two novel frameshift and nonsense mutations. The 
MTOR gene was mutated in 2 tumors (2.2%, Fig. 3), showing two previously described missense mutations in 
CRC, one affecting the PI3K/PI4K domain and one outside the main domains of the protein. AKT1 was mutated 
in 1 tumor (1.1%, Fig. 3) and showed one already known missense mutation affecting the Pleckstrin homology 
(PH) domain of the protein.
Notch signaling pathway alterations. The Notch signaling pathway was altered in 15 tumors (16.5%). 
FBXW7 was the most affected gene in this pathway, mutated in 10 tumors (10.9%, Fig. 4), showing nine already 
known mutations (7 missense and 2 frameshift mutations) and one novel somatic missense mutation. Most of the 
FBXW7 mutations (7, 70%) affected one of the repeated beta-transducin domains. One mutation (10%) affected 
the F-box-like domain, and 2 mutations were localized outside the main domains of the protein (Fig. 4b). The 
Figure 3. Waterfall (oncoplot) plot (a) and mutation mapper (b) of PI3K-AKT signaling pathway genes. Tumor 
stage: stage of the disease at diagnosis. MSI: microsatellite instability.
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NOTCH2 gene was altered in 3 tumors (3.3%, Fig. 4), all harboring novel missense mutations located at one of the 
repeats of the EGF-like domain (2 mutations) and one at the ankyrin repeat. The NOTCH1 gene was altered in 
three tumors (3.3%, Fig. 4) with 4 mutations, three already known mutations (2 missense and one nonsense muta-
tion) and one novel missense mutation. Two NOTCH1 mutations were localized at one of the ankyrin repeats and 
two outside of the main domains of the protein. Finally, the CREBBP gene was altered in 1 tumor (1.1%, Fig. 4), 
showing one already known frameshift mutation localized outside the main domains of the protein.
Receptor tyrosine kinase alterations. The receptor tyrosine kinase (RTK) family showed 9 altered genes 
(Fig. 5). ROS1 was altered in 3 tumors (3.3%, Fig. 5), showing one previously described missense mutation in 
the protein tyrosine kinase domain and two novel missense mutations outside the main domains of the protein. 
The ERBB4 gene was altered in 3 tumors (3.3%, Fig. 5), showing one novel missense mutation in the furin-like 
cysteine rich region of the protein, one previously described missense mutation in the protein tyrosine kinase 
domain, and one previously described missense mutation outside the main domains of the protein. ERBB3 was 
altered in 3 tumors (3.3%, Fig. 5), showing 1 already known missense mutation in the furin-like cysteine rich 
region of the protein and 2 novel missense mutations in growth factor receptor domain IV. The EGFR gene was 
altered in 2 tumors (2.2%, Fig. 5), showing 2 known missense mutations in the protein tyrosine kinase domain. 
The RET gene was mutated in 1 tumor (1.1%, Fig. 5), showing two novel mutations in the protein tyrosine kinase 
domain. The NTRK1 gene was mutated in 1 tumor (1.1%, Fig. 5), showing one novel missense mutation out-
side the main domains of the protein. The FLT3 gene was mutated in 1 tumor (1.1%, Fig. 5), showing one novel 
missense mutation in the protein tyrosine kinase domain. The FLT4 gene was altered in 1 tumor (1.1%, Fig. 5), 
showing one already known missense mutation in the immunoglobulin I-set domain. Finally, the ALK gene was 
also altered in 1 tumor (1.1%, Fig. 5) and showed one previously described missense mutation in the protein 
tyrosine kinase domain.
Figure 4. Waterfall (oncoplot) plot (a) and mutation mapper (b) of Notch signaling pathway genes. Tumor 
stage: stage of the disease at diagnosis. MSI: microsatellite instability.
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MSI status and its association with tumor mutation burden. We assessed the MSI status of tumor 
samples by multiplex PCR. Seventy-eight did not exhibit microsatellite instability (MSI-negative, 86.7%), and 
twelve tumors showed microsatellite instability (MSI-positive, 13.3%). The mean mutation burden of tumors 
that were MSI-positive was higher than MSI-negative tumors (7.1 ± 1.4 and 3.1 ± 0.2, respectively, P = 0.002, 
Supplementary Fig. S3). Tumors with MSI-positive status also showed a higher frequency of frameshift mutations 
(49.4% versus 13.2% in MSI-negative tumors, P < 0.001) and a lower frequency of missense (43.5% vs 59.1%, 
P = 0.01) and nonsense mutations (5.9% versus 26.4%, P < 0.001, Supplementary Fig. S3).
The profile of somatic mutations between tumors with and without MSI was also distinct. Somatic muta-
tions of mismatch repair (MMR) genes were found only in MSI-positive tumors, which showed four frameshift 
mutations on MSH6 and one nonsense in MLH1. Likewise, TGFBR2, NOTCH2, and STAT5B genes were exclu-
sively mutated in MSI-positive tumors (P < 0.001, P = 0.002 and P = 0.002, respectively, Table 1). Other genes 
also showed mutations only in MSI-positive tumors; however, there was no significant difference (Supplementary 
Table S2). MSI-positive tumors also had higher rates of BRAF mutations (41.7% vs 3.8%, P < 0.001), ATM muta-
tions (25% vs 3.8%, P = 0.029), BLM mutations (50% vs 1.3%, P < 0.001), NOTCH1 mutations (16.7% vs 1.3%, 
P = 0.046), CHEK2 mutations (16.7% vs 1.3%, P = 0.046) and ROS1 mutations (16.7% vs 0.3%, P = 0.046, Table 1).
In contrast, MSI-negative tumors showed a higher frequency of APC (75.6% vs 41.7%, p = 0.034) and TP53 
mutations (65.4% vs 8.3%, p < 0.001, Table 1), and some genes were exclusively altered in MSI-negative tumors, 
but without statistical significance (Supplementary Table S2).
Differences between proximal and distal colon. Of the 91 tumor samples sequenced, 71 (78%) were 
from the distal colon, and 20 (22%) were from the proximal colon. The proximal colon had a higher frequency of 
Figure 5. Waterfall (oncoplot) plot (a) and mutation mapper of RTK genes. Tumor stage: stage of the disease at 
diagnosis. MSI: microsatellite instability.
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MSI-positive tumors than the distal colon (50% versus 2.9%, P < 0.001). We found significant differences between 
the mutation profile of tumors from the proximal and distal colon (Fig. 1 and Table 1). Proximal colon tumors 
showed higher mutation frequencies than distal tumors on TGFBR2 (30.0% vs 2.8%, P < 0.001), ATM (20.0% vs 
2.8%, P = 0.020), BLM (25.0% vs 2.8%, P = 0.005), and PTEN (15.0% vs 1.4%, P = 0.032) genes. BRAF mutations 
were exclusively found in tumors from the proximal colon (40.0% vs 0.0%, P < 0.001), as well as mutations in 
the EGFR, JAK1, MAP2K4, MAP3K1, NBN, ALK genes (each of these mutated in 2 tumors), and BRCA1, BRIP1, 
CREBBP, FLT3, FLT4, MLH1, MPL and NT5C2 genes (each of these mutated in 1 tumor).
In contrast, the distal colon showed a higher frequency than the proximal colon of APC (77.5% vs 50.0%, 
P = 0.025), TP53 (67.6% vs 20.0%, P < 0.001) and KRAS (63.4% vs 15.0%, P < 0.001) gene mutations (Table 1). 
Mutations in NRAS (mutated in 4 tumors), ERBB3 (mutated in 3 tumors), RET, AKT1, AR, ARAF, BARD1, 
CDKN2A, GATA2, IDH2 MRE11A, NTRK1, PALB2 and SMO genes (each of these mutated in 1 tumor) were 
exclusively found in the distal colon.
Mutation profile and genetic ancestry markers. We further assessed the ancestry of the patients by a 
panel of ancestry informative markers (AIMs) to estimate the proportion of ancestral background. The proportion 
of European genetic ancestry was predominant in our study population (median 83.1%, interquartile range 76.6% 
and 87.8%), followed by Native American (median 4.1%, interquartile range 2.9% and 7.2%), Asian (median 3.4%, 
interquartile range 2.8% and 5.1%) and African (median 3.2%, interquartile 2.1% and 7.9%) (Supplementary Fig. S4).
Patients with the highest proportion of African ancestry (those with African ancestry proportions higher 
than 7.9%) had more frequent NF1 and BRAF mutations when compared with patients with intermediate and 
lowest proportions of African ancestry (P = 0.045 and 0.031, respectively, Supplementary Table S3). Patients with 
the highest proportion of Asian ancestry (those with a proportion of Asian ancestry higher than 5.1%) also had 
more NF1 mutations than those patients with intermediate and low Asian ancestry (P = 0.037, Supplementary 
Table S3). Patients with the highest proportion of Native American ancestry (those with a proportion of Native 
American ancestry higher than 7.2%) had fewer TP53 and PIK3CA mutations than those patients with the inter-
mediate and the lowest proportion of Native American ancestry (P = 0.002 and 0.024, respectively, Supplementary 
Table S3).
Discussion
In this study, we investigated mutations within 150 selected oncogenes and tumor suppressor genes in a Brazilian 
cohort. To the best of our knowledge, this is the largest mutation profile study in this population. Overall, our 
results showed that our population had a similar mutation profile to other populations (Table 2), with alterations 
in canonical driver genes, such as APC, KRAS, TP53, PIK3CA, and FBXW7. The differences between the proxi-
mal and distal colon were also highlighted in Brazilian patients, and the admixed features of our population were 
revealed by ancestry markers.










P valuen (%) n (%) n (%) n (%)
APC 59 (75.6) 5 (41.7) 0.034** 10 (50.0) 55 (77.5) 0.025*
TP53 51 (65.4) 1 (8.3) <0.001* 4 (20.0) 48 (67.6) <0.001*
KRAS 45 (57.7) 3 (25.0) 0.059* 3 (15.0) 45 (63.4) <0.001*
PIK3CA 12 (15.4) 2 (16.7) 0.999** 4 (20.0) 10 (14.1) 0.499**
FBXW7 8 (10.3) 2 (16.7) 0.617** 2 (10.0) 8 (11.3) 0.999**
NF1 5 (6.4) 3 (25.0) 0.070** 3 (15.0) 5 (7.0) 0.367**
TGFBR2 0 (0.0) 8 (66.7) <0.001** 6 (30.0) 2 (2.8) 0.001**
ATM 3 (3.8) 3 (25.0) 0.029** 4 (20.0) 2 (2.8) 0.020**
BRAF 3 (3.8) 5 (41.7) 0.001** 8 (40.0) 0 (0.0) <0.001**
BLM 1 (1.3) 6 (50.0) <0.001** 5 (25.0) 2 (2.8) 0.005**
MSH6 0 (0.0) 4 (33.3) <0.001** 2 (10.0) 2 (2.8) 0.209**
NOTCH1 1 (1.3) 2 (16.7) 0.046** 1 (5.0) 2 (2.8) 0.530**
NRAS 4 (5.1) 0 (0.0) 0.999** 0 (0.0) 4 (5.6) 0.572**
PTEN 2 (2.6) 2 (16.7) 0.084** 3 (15.0) 1 (1.4) 0.032**
CHEK2 1 (1.3) 2 (16.7) 0.046** 1 (5.0) 2 (2.8) 0.530**
ERBB3 3 (3.8) 0 (0.0) 0.999** 0 (0.0) 3 (4.2) 0.999**
ERBB4 3 (3.8) 0 (0.0) 0.999** 1 (5.0) 2 (2.8) 0.530**
NOTCH2 0 (0.0) 3 (25.0) 0.002** 2 (10.0) 1 (1.4) 0.120**
ROS1 1 (1.3) 2 (16.7) 0.046** 2 (10.0) 1 (1.4) 0.120**
STAT5B 0 (0.0) 3 (25.0) 0.002** 2 (10.0) 1 (1.4) 0.120**
Table 1. Mutation profile of the most frequently altered genes in our study population by microsatellite 
instability status and tumor site. *Chi-squared test; **Fisher Exact Test; MSI: microsatellite instability.
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APC mutations are a common event in CRC, being an early and a general event for tumorigenesis progres-
sion14. Here, we showed that APC was the most frequently mutated gene, similar to several other studies demon-
strated in different populations7,15–17 (Table 2). Additionally, as previously reported, we found that APC mutations 
were more frequent in distal colon and MSI-negative tumors6,16.
TP53 is a ubiquitous driver gene in several cancer types18, and one of the most frequently altered genes in 
colorectal cancer, ranging from 51.7 to 68% of the cases7,16,19,20 (Table 2). Our study population showed a simi-
lar frequency of TP53 gene alterations when compared with the TCGA frequency and studies in other popula-
tions7,21, showing the highest frequency in non-hypermutated tumors (MSI-negative tumors) and in distal colon 
tumors7,17,22,23.
The MAPK-ERK signaling pathway is significantly altered in CRCs and other tumors18. This pathway is con-
stitutively activated by alterations in several driver genes, including KRAS, BRAF, and NRAS7. We observed that 
68% of cases had a mutation in at least one gene in the MAPK-ERK pathway, in accordance with TCGA data 
(59.3%)7,17. Individually, we observed a high frequency of KRAS mutations (52.7%) that was slightly higher than 
the one reported in TCGA data (42%) and those found in other populations15,17,21,24 (Table 2). Moreover, pre-
vious studies on the prevalence of KRAS mutations carried out in Brazilian populations showed a lower fre-
quency (31.9–49.2%) of mutations25,26. The higher frequency observed in the present study in comparison to 
those observed in other Brazilian studies may be associated with the higher sensitivity and coverage of the NGS 
approach used in our study and the high prevalence of early-stage and localized disease cases included in our 
study (78% stages 0, I and II). In agreement with other studies, most mutations in the KRAS gene were found at 
protein residues 12 and 13, with predominant Gly12Asp mutations11,27. Epidemiological and molecular observa-
tions showed that the proximal and distal colon exhibited distinct features. KRAS mutations are slightly higher 
in the proximal colon20,28,29. However, in our study, a predominance of KRAS mutations was observed in tumors 
from the distal colon. We also found a high mutation frequency in the NF1 gene (Table 2), and interestingly, this 
frequency was associated with a high proportion of Asian ancestry, corroborating the known higher frequency of 












Salem et al. 
(2413)
N (%) N (%) N (%) N (%) N (%) N (%)
APC 65 (71.4) 168 (75.0) 361 (58.3) 29 (40.3) 173 (53.9) 1513 (62.7)
TP53 51 (56.0) 121 (54.0) 320 (51.7) 40 (55.6) 158 (49.2) 1641 (68.0)
KRAS 48 (52.7) 94 (42.0) 173 (27.9) 37 (51.4) 118 (36.8) 1156 (47.9)
PIK3CA 14 (15.4) 45 (20.1) 132 (21.3) 22 (30.6) 60 (18.7) 326 (13.5)
FBXW7 10 (11.0) 37 (16.5) 86 (13.9) 15 (20.8) 59 (18.4) — —
BRAF 8 (8.8) 21 (9.4) 127 (20.5) 6 (8.3) 51 (15.9) 168 (7.0)
NF1 8 (8.8) 8 (3.6) 45 (7.3) 4 (5.6) 66 (20.6) — —
TGFBR2 8 (8.8) 23 (10.3) 29 (4.7) 2 (2.8) 25 (7.8) — —
BLM 7 (7.7) 10 (4.5) 12 (1.9) 0 (0.0) 25 (7.8) — —
ATM 6 (6.6) 25 (11.2) 64 (10.3) 13 (18.1) 53 (16.5) 34 (1.4)
MSH6 4 (4.4) 15 (6.7) 27 (4.4) 3 (4.2) 25 (7.8) — —
NRAS 4 (4.4) 20 (8.9) 27 (4.4) 2 (2.8) 17 (5.3) — —
PTEN 4 (4.4) 8 (3.6) 51 (8.2) 4 (5.6) 30 (9.3) 37 (1.5)
ERBB3 3 (3.3) 14 (6.3) 36 (5.8) 6 (8.3) 31 (9.7) — —
ERBB4 3 (3.3) 19 (8.5) 37 (6.0) 8 (11.1) 46 (14.3) — —
NOTCH1 3 (3.3) 0 (0.0) 65 (10.5) 6 (8.3) 38 (11.8) — —
CHEK2 3 (3.3) 1 (0.4) 36 (5.8) 5 (6.9) 22 (6.9) — —
NOTCH2 3 (3.3) 12 (5.4) 25 (4.0) 4 (5.6) 63 (19.6) — —
ROS1 3 (3.3) 13 (5.8) 31 (5.0) 2 (2.8) 46 (14.3) — —
STAT5B 3 (3.3) 3 (1.3) 15 (2.4) 3 (4.2) 12 (3.7) — —
BRCA2 2 (2.2) 10 (4.5) 42 (6.8) 5 (6.9) 35 (10.9) — —
BRD2 2 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 16 (5.0) — —
EGFR 2 (2.2) 10 (4.5) 28 (4.5) 4 (5.6) 53 (16.5) — —
JAK1 2 (2.2) 4 (1.8) 19 (3.1) 2 (2.8) 25 (7.8) — —
MAP2K4 2 (2.2) 11 (4.9) 13 (2.1) 2 (2.8) 16 (5.0) — —
MAP3K1 2 (2.2) 5 (2.2) 26 (4.2) 1 (1.4) 28 (8.7) — —
MTOR 2 (2.2) 17 (7.6) 50 (8.1) 8 (11.1) 42 (13.1) — —
NBN 2 (2.2) 2 (0.9) 20 (3.2) 1 (1.4) 26 (8.1) — —
Table 2. Comparison of mutation frequency across different public data (cBioPortal) and studies. TCGA: 
Comprehensive molecular characterization of human colon and rectal cancer7; DFCI: Genomic Correlates 
of Immune-Cell Infiltrates in Colorectal Carcinoma15; Genentech: Recurrent R-spondin fusions in colon 
cancer19; ICGC: COCA-CN: Colorectal cancer from non-Western samples (China)30; Salem et al.: Comparative 
molecular analyses of left-sided colon, right-sided colon, and rectal cancers20.
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BRAF mutations are reported in less than 10% of cases (Table 2) and have been related to MSI-positive and 
proximal colon tumors in several studies6,7,17,20. Here, we confirmed these observations and found a similar 
overall frequency of BRAF mutations, including the predominance of activating V600E type mutation31. Some 
non-V600E mutations, such as mutations at the D594 site, were shown to have either impaired or complete loss of 
kinase activity32, although constitutive activation of MAPK-ERK by these mutations has been shown to coincide 
with other mechanisms of activation, such as NF1 deletions33. Non-V600E, such as the G469V mutation found 
here, has high kinase activity but acts in a different way than the V600E mutation33. The NRAS gene showed a 
lower frequency of mutation compared to the TCGA data, but it was similar to other large-scale studies (Table 2). 
Moreover, the significant pattern of mutually exclusivity of KRAS, BRAF and NRAS mutations found here has 
been observed in several studies7,15,17,34.
The PI3K pathway is another common pathway altered in CRC, leading to cell survival when activated7,10,18. 
Data from TCGA showed that genes from the PI3K signaling pathway were altered in approximately 25.9% of 
patients7,17, similar to the frequency reported in our study (23.1%). The PIK3CA gene seems to be the principal 
gene mutated in this pathway in CRCs7,15, showing activating mutations mainly on the PI3Ka domain (helicase), 
in addition to other already known activating mutations, such as H1047R and N345K/S found in the present 
study7,35. The PTEN gene is known to revert the action of PI3Ks36, and its inactivation is observed at a lower fre-
quency in CRCs7 (1.5–9.3%, Table 2) by mutation7,37, as reported in our study (4.4%). The association between 
PTEN mutations and proximal colon localization has been observed previously23. Although MTOR was found 
to be mutated in CRCs with a range of 7.6–13.1% in large cohort studies (Table 2), these mutations are poorly 
characterized38. Mutations in MTOR site S2215, as we found here, seems to be the most frequently altered site 
across diverse cancer types and has been shown to increase the activity of mTOR protein38. The other MTOR 
(T2444M) mutation observed here has not been well characterized, but it affects the C-terminal region related to 
mTOR activation38. A low frequency of AKT1 has been found across large cohort studies (Table 2), and the E17K 
mutation observed here has been related to the constitutive activation of AKT1 protein39.
We found that 15.4% of tumors harboring missense mutations in members of the RTK family were lower 
than the frequency observed in TCGA data (22.3%)7,17. Although activating events in some RTK proteins can be 
observed by rearrangements in CRCs, such as ROS140, NTRK140, ALK40, and RET41, missense mutations in these 
genes are found across several studies (Table 2), but the oncogenic potential of such mutations is not completely 
understood in CRC. RET missense mutations promote tumor progression in thyroid cancer42 and are shown to 
reduce apoptosis in colorectal cancer cell lines42. Interestingly, ALK, ROS1, and NTRK1 missense mutations have 
been observed in solid tumors resistant to tyrosine receptor kinase inhibitors43–45.
We found known activating mutations present in the protein kinase domain EGFR T725M17,46 and P848L47, as 
well as in FLT317,46. Other mutations affecting the protein kinase domain of the ROS1, ERBB4, and ALK genes were 
also observed, but their role in oncogeneses is unknown47. Mutations that occur outside the protein kinase domain 
also play a role in the activation of RTKs, such as ERBB3 mutations, which promote the growth of colonic cells48 and 
ERBB4 mutations, which promote an increase in the kinase activity and transformation ability in melanoma cells49.
The Notch signaling pathway is important in maintaining the proliferative compartment of intestinal crypts50 
and has been linked to tumor progression51. Here, we observed gene alterations in this pathway in 16.5% of the 
tumors, which was slightly lower when compared to the frequency observed on TCGA data for the same path-
way (20.1%)7,17. FBXW7 is one of the regulators of Notch protein52,53, and its loss seems to lead to the activation 
of this pathway54. The frequency of FBXW7 mutations in our population was compared with those reported in 
other populations (Table 2)55. We observed mutations affecting hotspots of FBXW7, such as residues 465 and 
505, that are important sites for substrate binding56, and frameshift mutations that lead to premature termination 
of the protein and have also been found affecting this gene7,15,17. The frequency of alterations in NOTCH1 and 
NOTCH2 genes is variable (Table 2), and missense activating mutations in both NOTCH1 and NOTCH2 have 
been observed in hematological tumors57,58. The pattern of mutual exclusivity between mutations in the NOTCH2 
and FBXW7 genes that we found here has not been observed in large cohort studies7,15,17.
The presence of MSI was found in 13.3% of cases, in accordance with previous studies4,6,59. In addition, MSI 
was associated with tumors in the proximal colon and with those exhibiting a higher mutation burden6,7,19. As 
previously reported, we observed an association between ATM7,17, BLM7,17, and TGFRB26,7,17 mutations and MSI 
and the proximal colon.
Epidemiological evidence suggests that ethnicity has a high impact on cancer incidence and mortality60, and dif-
ferences in the prevalence of cancer driver mutations have been observed in several cancer types, including CRC61. 
Our population is known to be diverse62, and our results are in agreement with these observations, showing dif-
ferences in the proportions of each of the main four population origins compared with previous studies62,63. Our 
patients with a higher African ancestry proportion had a higher frequency of BRAF mutations, contrasting with a 
previous study by Staudacher et al.64. We did not observe an association between the frequency of KRAS mutations 
and the African ancestry that was reported previously64. These disparities may reside in the fact that, although we 
have an admixture population study, we have a low frequency of self-declared African ancestry and a low frequency 
of proportion of African ancestry than observed in other population studies62,63. In contrast, the association of NF1 
mutations and African ancestry has been observed previously65. Moreover, the observation that NF1 mutations were 
associated with the high Asian ancestry proportion was consistent with the data from ICGC30. Although ethnicity 
association with PIK3CA mutations has been observed in different populations65,66, this is the first study to demon-
strate an inverse correlation between PIK3CA mutations and a high Native American ancestry background.
Despite the major findings, one limitation of the present study lies in the preselection of a panel of known 
cancer genes, and known genes related to CCR carcinogenesis were not included in the analysis, such as 
SMAD4 (altered in 11.6–12.9% of CRC), TTN (35.7–48.1%) and SYNE1 (21.0–48.1%)7,15,17. Moreover, using 
whole-genome or exome approaches, other putative CCR cancer-related genes could have been identified in the 
Brazilian context.
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In conclusion, our study constitutes the largest mutation landscape of Brazilian colorectal cancer patients. This 
study paves the way for a better comprehension of the major alterations identified and could guide better-tailored 
therapy for colorectal cancer in the Brazilian population.
Characteristics (N = 91)
Frequency (%)
Mean (range)












    Ascending colon 9 45.0
    Transverse colon 7 35.0
    Left-sided 71 78.0
    Sigmoid colon 31 43.7














    T4 (a,b) 10 11.0
Regional Lympho Nodes (N)
    N0 69 75.8
    N1 (a,b,c) 15 16.5









Angiolymphatic invasion (n = 90) 17 18.9
Perineural invasion (n = 86) 6 7.0
Adjuvant chemotherapy 30 33.0
Radiotherapy (n = 90) 4 4.4
Tumor Recurrence (n = 89) 3 3.4
MSI (n = 90)
    MSI-negative 78 86.7
    MSI-positive 12 13.3
Table 3. Characteristics of the study population.
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Materials and Methods
Tissue samples. Ninety-one patients diagnosed with colorectal adenocarcinomas and admitted for a surgical 
procedure at Barretos Cancer Hospital, Barretos, SP, Brazil, were evaluated. The main clinicopathological features 
are summarized in Table 3. The mean age of patients was 61 years old, and the majority of cases had early-stage 
and localized disease (0, I and II).
All included patients signed an informed consent form. Both tumors and blood were obtained and 
immediately processed and stored at −80 °C at Barretos Cancer Hospital Biobank. The present study was 
approved by the Barretos Cancer Hospital Institutional Review Board (Project n° 1060/2015, protocol CAAE: 
51770115.6.0000.5437). All methods were performed in accordance with the relevant guidelines and regulations.
DNA isolation. Tumor DNA was isolated from fresh-frozen tissue using the QIAsymphony DNA Mini Kit 
following the Tissue_200 protocol for automated isolation in the QIAsymphony (QIAGEN, Hilden, Germany). 
DNA from leucocytes of peripheral blood was isolated using the QIAmp DNA Blood Mini Kit (QIAGEN, Hilden, 
Germany) following the manufacturer’s instructions. DNA quantity and quality were assessed by Qubit (Thermo 
Fisher Scientific, Waltham, MA, USA).
Microsatellite instability analyses. The MSI status was evaluated using a multiplex PCR comprising six 
quasi-monomorphic mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24, NR-27 and HSP110) as 
described previously59. The MSI analyses were performed using GeneMapper v4.1 software (Applied Biosystems), 
and the status was classified as stable (MSS) when none of the markers were unstable. The status was MSI-Low 
(MSI-L) when one of the markers was unstable and MSI-positive when two or more of the markers were unstable. 
MSS and MSI-L were considered MSI-negative59.
Mutation profile. The mutation profile of a commercial panel of 150 cancer-related genes (for a list of genes, 
see Supplementary Information) was conducted at the Mendelics Genetics company (São Paulo, SP, Brazil, 
(https://www.mendelics.com/oncologia/). The panel analyzed all coding regions of the 150 cancer-related genes. 
For sequencing, paired tumor and blood DNA libraries were prepared using the Nextera Rapid Capture Custom 
Enrichment Kit (Illumina, San Diego, CA, USA). Libraries were quantified using a Qubit fluorometer (Thermo 
Fisher Scientific, Waltham, MA, USA), and their quality was evaluated using an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA, USA). Cluster generation and sequencing were performed on the Illumina 
HiSeq. 4000 following the manufacturer’s instructions. Paired-end reads from Illumina sequencing were pro-
cessed by script bcl2fastq (v. 2.17.1.14) and aligned against the human genome reference build GRCh37 using 
Burrows-Wheeler Aligner (BWA, version 0.7.13)67. The somatic variants were called by a VarScan2 algorithm68. 
The variants with artifacts due to indel reads at their position or less than 10% or more than 90% of variant sup-
porting reads on one strand were removed. The variants were further filtered to remove those with fewer than 
10 reads covering the variant and with less than 5% variant allele frequency. The annotation of variants was per-
formed using Ensembl Variant Effect Predictor (VEP)69.
To identify driver mutations on tumors, we used the Cancer Genome Interpreter – CGI70. After the classifi-
cation of mutations by the CGI, we excluded mutations that were not classified as cancer driver mutations or not 
predicted as a driver by the OncoMut algorithm that CGI used. Therefore, mutations identified as polymorphisms 
(high allele frequency) or those predicted as neutral or passenger for oncogenesis, and those found in DNA 
sequences outside coding regions were excluded.
We further validated mutations on codons 12/13 and codon 61 of the KRAS gene using the cobas® KRAS 
Mutation Test (F. Hoffmann-La Roche, Basel, Switzerland) following the manufacturer’s recommendations. We 
also performed PCR-followed by direct Sanger sequencing for a subset of samples to confirm mutations in the 
APC and TP53 genes. The PCR and Sanger sequencing conditions were previously reported by our group71,72
Genetic ancestry markers. The genetic ancestry of patients was determined by 46 autosomal ancestry 
informative markers (AIMs), consisting of insertion and deletion polymorphisms and using the genetic data of 
the Human Genome Diversity Project – center d’Etude du Polymorphisme Humain (HGDP-CEPH), according 
to Pereira et al.63. We classified the proportion of ancestry by tertiles as high, intermediary and low for each of the 
main populations: African, European, Asian and Native American73.
Statistical analyses. Chi-square and Fisher’s exact tests were used to set differences between mutated 
and nonmutated genes and patient characteristics. Mutation types and mutation burden differences between 
MSI-positive and MSI-negative tumors were determined by chi-square and Mann-Whitney tests, respectively. All 
statistical analyses were performed using SPSS software (v.20) and R 3.5.0 software. Mutation mapper figures were 
generated using cBioPortal. Oncoplots and ancestry charts were generated using GenVisR and ggplot2 packages 
(versions 1.14 and 3.1.0, respectively) in R 3.5.0 software.
Data Availability
Data that support the findings are available from Dr. Denise Peixoto Guimarães and Dr. Rui Manual Reis and 
are not publicly available due patient personal information. However, these data are available upon reasonable 
request and with permission of the Dr. Rui Manuel Reis (Scientific and Executive Director of the Molecular On-
cology Research Center, Barretos Cancer Hospital).
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